We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients.
- Authors
Nsiangani Lusambo, Nadine; Kaimbo Wa Kaimbo, Dieudonné; Ngoyi Mumba, Dieudonné Mumba; de-la-Torre, Alejandra
- Abstract
Background: Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP/SMX) has been presented as an attractive alternative to the "classic' treatment therapy (Pyrimethamine/Sulfadiazine). Methods: A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients. Results: 54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment. Conclusion: TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.
- Subjects
KINSHASA (Congo); TOXOPLASMOSIS; RESOURCE-limited settings; SULFAMETHOXAZOLE; ADVERSE health care events; TERMINATION of treatment
- Publication
BMC Ophthalmology, 2023, Vol 23, Issue 1, p1
- ISSN
1471-2415
- Publication type
Article
- DOI
10.1186/s12886-023-03183-x